SEARCH

SEARCH BY CITATION

References

  • 1
    Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003;125:16601669.
  • 2
    Straumann A, Bauer M, Fischer B, Fischer B, Blaser K, Simon H-U. Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response. J Allergy Clin Immunol 2001;108:954961.
  • 3
    Gupta SK, Fitzgerald JF, Kondratyuk T, HogenEsch H. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2006;42:2226.
  • 4
    Furuta GT, Liacouras C, Collins MH, Gupta S, Justinich C, Putnam P et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:13421363.
  • 5
    Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:320.
  • 6
    Dellon ES. Diagnosis and management of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:10661078.
  • 7
    Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2009;7:10551061.
  • 8
    DeBrosse CW, Collins MH, Buckmeier Butz BK, Allen CL, King EC, Assa'ad AH et al. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982–1999. J Allergy Clin Immunol 2010;126:112119.
  • 9
    Hruz P, Straumann A, Bussmann C, Heer P, Simon HU, Zwahlen M et al. Escalating incidence of eosinophilic esophagitis: a 20 year prospective, population-based study in Olten County Switzerland. J Allergy Clin Immunol 2011;128:13491350.
  • 10
    Ronkainen J, Talley NJ, Aro P, Storskrubb T, Johansson SE, Lind T et al. Prevalence of esophageal eosinophils and eosinophilic esophagitis in adults: the population-based Kalixanda study. Gut 2007;56:615620.
  • 11
    Desai TK, Stecevic V, Chang CH, Goldstein NS, Badiazdegan K, Furuta GT. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc 2005;61:795801.
  • 12
    Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy 2012;67:477490.
  • 13
    Straumann A, Bussmann C, Zuber M, Vannini S, Simon HU, Schoepfer AM. Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol 2008;6:598600.
  • 14
    Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia PJ et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology 2008;134:204214.
  • 15
    Aceves SS, Newbury RO, Chen D, Mueller J, Dohil R, Hoffman H et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 2010;65:109116.
  • 16
    Lucendo AJ, Arias A, De Rezende LC, Yague-Compadre JL, Mota-Huertas T, Gonzalez-Castillo S et al. Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study. J Allergy Clin Immunol 2011;128:10371046.
  • 17
    Liacouras CA, Wenner WJ, Brown K, Ruchelli E. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998;26:380385.
  • 18
    Schaefer ET, Fitzgerald JF, Molleston JP, Croffie JM, Pfefferkorn MD, Corkins MR et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165173.
  • 19
    Faubion WA, Perrault J, Burgart LJ, Zein NN, Clawson ML, Freese DK. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr 1998;27:9093.
  • 20
    Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology 2002;122:12161225.
  • 21
    Arora AS, Perrault J, Smyrk TC. Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc 2003;78:830835.
  • 22
    Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:13811391.
  • 23
    Lucendo AJ, Pascual-Turrión JM, Navarro M, Comas C, Castillo P, Letrán A et al. Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series. Endoscopy 2007;39:765771.
  • 24
    Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418429.
  • 25
    Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel HJ et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139:15261537.
  • 26
    Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC. Comparison of esomeprazole to aerosolized swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010;55:13131319.
  • 27
    Straumann A, Conus S, Degen L, Frei C, Bussmann Ch, Beglinger Ch et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011;9:400409.
  • 28
    Lucendo AJ, De Rezende LC, Jimenez-Contreras S, Yague-Compadre JL, Gonzalez-Cervera J, Mota-Huertas T et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011;56:35513558.
  • 29
    Straumann A, Conus S, Grzonika P, Kita H, Kephart G, Bussmann Ch et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010;59:2130.
  • 30
    Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011;141:15931604.
  • 31
    Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129:456463.
  • 32
    Straumann A, Bussmann Ch, Conus S, Beglinger Ch, Simon HU. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 2008;122:425427.
  • 33
    Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007;6:313325.
  • 34
    Kanda N, Ishikawa T, Watanabe S. Prostaglandin D2 induces the production of human beta-defensin-3 in human keratinocytes. Biochem Pharmacol 2010;79:982989.
  • 35
    Pettipher R, Vinall SL, Xue L, Speight G, Townsend ER, Gazi L et al. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012;340:473482.
  • 36
    Barnes N, Pavord I, Chuchalin A, Bell J, Hunter M, Lewis T et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012;42:3848.
  • 37
    Gonsalves N, Policarpio-Nicolas M, Zhang Q, Rao S, Hirano I. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313319.
  • 38
    Shah A, Kagalwalla AF, Gonsalves N, Melin-Aldana H, Li BU, Hirano I. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009;104:716721.
  • 39
    Arora AS, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol 2004;2:523530.
  • 40
    Alexander JA, Katzka DA. Eosinophilic esophagitis: it is here to stay. Clin Gastroenterol Hepatol 2011;9:370372.
  • 41
    Straumann A. Treatment of eosinophilic esophagitis: diet, drugs or dilation? Gastroenterology 2012;142:14091411.
  • 42
    Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 2010;11:289293.
  • 43
    Wong CK, Hu S, Cheung PF, Lam CW. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol 2010;43:305315.
  • 44
    Morshed M, Yousefi S, Stoeckle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 2012;67:11271137.